Global Soft Tissue Sarcoma Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2023-2030. Soft tissue sarcoma is a type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, nerves, blood vessels, and connective tissues. A lump or swelling in a body’s soft tissue is an indication of soft tissue sarcoma. There are many different locations on the body where soft tissue sarcomas develop, which is identified through biopsy. The global market growth is driven by factors such as the rising adoption of novel therapies, growing focus on personalized medicine, escalating population, and increasing healthcare expenditure, coupled with favorable reimbursement policies.
In addition, the surge in the incidences of cancer is acting as a catalyzing factor for market growth across the globe. According to the World Health Organization, in 2020, it was estimated that around 19.3 million new cancer cases were recorded globally, which is projected to increase and likely to reach 30.3 million cases by the year 2040. Thus, these aforementioned factors are propelling the growth of the soft tissue sarcoma market during the estimated period. Moreover, the rising advancements in diagnostics and treatment options, as well as increasing investments in research and development is presenting various lucrative opportunities over the forecasting years. However, the high cost of treatments and the side effects of soft tissue sarcoma drugs are hampering the market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Soft Tissue Sarcoma Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the surging demand for targeted therapies, rising focus on personalized medicine, and the presence of well-established healthcare facilities. Whereas, Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as the rising prevalence of soft tissue sarcoma, increasing healthcare expenditure, and growing investments in research and development.
Major market players included in this report are:
F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Merck & Co., Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Recent Developments in the Market:
Ø In 2019, Pfizer announced that Vitrakvi (larotrectinib) had received European Commission approval for the treatment of advanced soft tissue sarcoma. Vitrakvi – a targeted medication is available to patients whose tumours have a particular genetic mutation.
Ø In 2019, Johnson & Johnson declared that the US Food and Drug Administration had authorized JNJ-4528 as a medication for the management of relapsed or refractory multiple myeloma. JNJ-4528 is a CAR-T cell therapy that is developed for use in the treatment of several malignancies, including some types of sarcomas.
Global Soft Tissue Sarcoma Market Report Scope:
ü Historical Data – 2020 – 2021
ü Base Year for Estimation – 2022
ü Forecast period – 2023-2030
ü Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
ü Segments Covered – Treatment, Route of Administration, End-users, Region
ü Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa
ü Customization Scope – Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment:
Targeted Therapy
Chemotherapy
Anti-Angiogenesis Drugs
Radiation Therapy
By Route of Administration:
Oral
Parenteral
Others
By End-users:
Hospitals
Homecare
Speciality Centres
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa